{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","estimateComment":"Zoledronic acid versus placebo group","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.29","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Adjusted for stratification factors: performance status, prior SRE, and serum alkaline phosphatase.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.2","upperLimit":"49.2","value":"37.9"},{"groupId":"OG001","lowerLimit":"30.2","upperLimit":"41.6","value":"36.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).","id":"OG000","title":"Zoledronic Acid + Androgen Deprivation Therapy"},{"description":"Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.","id":"OG001","title":"Placebo + Androgen Deprivation Therapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 10 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}